CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.8
63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
CSPC Innovation Pharmaceutical Co Ltd
Gross Profit
CSPC Innovation Pharmaceutical Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Gross Profit
ÂĄ795.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Gross Profit
ÂĄ12B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Gross Profit
ÂĄ3.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
16%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Gross Profit
ÂĄ26.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Gross Profit
ÂĄ11.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Gross Profit
ÂĄ5.5B
|
CAGR 3-Years
111%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
CSPC Innovation Pharmaceutical Co Ltd
Glance View
Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.
See Also
What is CSPC Innovation Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
795.1m
CNY
Based on the financial report for Sep 30, 2025, CSPC Innovation Pharmaceutical Co Ltd's Gross Profit amounts to 795.1m CNY.
What is CSPC Innovation Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
2%
Over the last year, the Gross Profit growth was -6%. The average annual Gross Profit growth rates for CSPC Innovation Pharmaceutical Co Ltd have been -3% over the past three years , 2% over the past five years .